Women who inherit a deleterious BRCA1 or BRCA2 mutation face substantially increased
risks of developing breast cancer, which is estimated at 70%. Although annual screening …

Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy,
resulting in considerable undertreatment or overtreatment. New insights into the role of …

Breast cancer is a global burden with a woman's lifetime risk of developing breast cancer at
1 in 8. Although breast cancer is a disease that affects mostly women, the lifetime risk in men …

Background: Whether oophorectomy reduces breast cancer risk among BRCA mutation
carriers is a matter of debate. We undertook a prospective analysis of bilateral …

Purpose Chemoprevention with a selective estrogen receptor modulator (tamoxifen or
raloxifene) is a non-surgical option offered to high-risk women to reduce the risk of breast …

Genetic testing for BRCA mutations is expanding in clinical oncology centers worldwide.
Testing may help target unaffected high-risk women for prevention and/or close surveillance …

BRCA1/2 mutation carriers are at a higher risk of breast cancer and of subsequent
contralateral breast cancer (CBC). This study aims to evaluate the evidence of the effect of …

Background The risk of developing metachronous contralateral breast cancer (CBC) is a
recurrent topic at the outpatient clinic. We aimed to provide CBC risk estimates of published …

Population-based estimates are lacking for the temporal trends in the contralateral breast
cancer (CBC) risk for patients with breast cancer (BC). Data for BC patients diagnosed with …

Given the greatly elevated risks of contralateral breast cancer (CBC) observed in breast
cancer patients who carry mutation in BRCA1 or BRCA2, the present meta-analysis was …